Business Description
Alzinova AB
ISIN : SE0007413455
Compare
Compare
Traded in other countries / regions
ALZ.Sweden78D.Germany IPO Date
2015-11-25Description
Alzinova AB is a Swedish biotechnology company engaged in the discovery and development of therapeutics for the treatment of Alzheimer's disease. The company is also engaged in development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody. The product is in clinical development as a therapeutic vaccine for the treatment of Alzheimer's.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 41.13 | |||||
| Equity-to-Asset | 0.94 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.05 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 9.3 | |||||
| 3-Year EPS without NRI Growth Rate | 9.4 | |||||
| 3-Year FCF Growth Rate | 4.4 | |||||
| 3-Year Book Growth Rate | -15.1 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 32.93 | |||||
| 9-Day RSI | 37.85 | |||||
| 14-Day RSI | 39.27 | |||||
| 6-1 Month Momentum % | -23.19 | |||||
| 12-1 Month Momentum % | -26.06 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.91 | |||||
| Quick Ratio | 4.91 | |||||
| Cash Ratio | 4.74 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -42.9 | |||||
| Shareholder Yield % | -34.04 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -14.78 | |||||
| ROA % | -14.05 | |||||
| ROIC % | -19.09 | |||||
| ROCE % | -14.63 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.65 | |||||
| Price-to-Tangible-Book | 2.88 | |||||
| EV-to-EBIT | -2.7 | |||||
| EV-to-Forward-EBIT | -1.09 | |||||
| EV-to-EBITDA | -2.7 | |||||
| EV-to-Forward-EBITDA | -1.09 | |||||
| EV-to-Forward-Revenue | 3.32 | |||||
| EV-to-FCF | -1.49 | |||||
| Price-to-Net-Current-Asset-Value | 2.88 | |||||
| Price-to-Net-Cash | 2.98 | |||||
| Earnings Yield (Greenblatt) % | -36.93 | |||||
| FCF Yield % | -40.66 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Alzinova AB Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | |||
| EPS (TTM) (kr) | -0.46 | ||
| Beta | 0 | ||
| Volatility % | 46.61 | ||
| 14-Day RSI | 39.27 | ||
| 14-Day ATR (kr) | 0.142884 | ||
| 20-Day SMA (kr) | 1.8031 | ||
| 12-1 Month Momentum % | -26.06 | ||
| 52-Week Range (kr) | 1.666 - 3.915 | ||
| Shares Outstanding (Mil) | 44.53 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Alzinova AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Alzinova AB Stock Events
| Event | Date | Price(kr) | ||
|---|---|---|---|---|
| No Event Data | ||||
Alzinova AB Frequently Asked Questions
What is Alzinova AB(OSTO:ALZ)'s stock price today?
The current price of OSTO:ALZ is kr1.70. The 52 week high of OSTO:ALZ is kr3.92 and 52 week low is kr1.67.
When is next earnings date of Alzinova AB(OSTO:ALZ)?
The next earnings date of Alzinova AB(OSTO:ALZ) is 2024-05-17 Est..
Does Alzinova AB(OSTO:ALZ) pay dividends? If so, how much?
Alzinova AB(OSTO:ALZ) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers